In addition to positively regulating Erk1/2, AMPK can also affect the energy metabolism oxidative phosphorylation involved in mitochondrial dynamics, making it a potential therapeutic target for craniosynostosis. The gene discussed is MAPK3; the disease is craniosynostosis.